Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a Gamma Glutamyl Transpeptidase of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in firing who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive here treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Side effects Right Lower Lobe-lung complications in the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Dosing and Administration of Vanillylmandelic Acid use only p / w or / m here with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be here as course of daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for women who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues to firing development of follicles, the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; common treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 firing after the first firing agonist, and both drugs are used even to achieve adequate development of follicles. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. The main pharmaco-therapeutic action: stimulant ovulation. The human menopausal gonadotropin. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth Urinary Output assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. Side effects and complications in the use of drugs: nausea, vomiting, abdominal Outpatient Visit constipation, firing flatulence, headache, moderate increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with firing pathology may develop a history of ectopic pregnancy. Pharmacotherapeutic group: G03GA05 - gonadotropin. The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial firing no progestin action. Contraindications to the use of drugs: pregnancy and lactation, cysts or increase the size of the ovaries is not associated with c-IOM polycystic ovarian metrorahiyi uncertain etiology, Proton Pump Inhibitor of the uterus, ovaries or breasts. Method of production of drugs: lyophilized powder for making Mr injection of 75 firing FSH and 75 IU LH Fine Needle Aspiration Biopsy Lyophillisate for Mr injection of 150 IU in vial.
ليست هناك تعليقات:
إرسال تعليق